Table 2 Predictors for percentage DXR–MCI loss at 104 weeks follow-up in 515 RA patients explored by a multivariate linear regression model

	DXR–MCI percentage change at 104 weeks
	Beta	p Value
Age, years	−0.25	<0.001
Female gender	−0.04	0.36
Disease duration, years	0.06	0.11
C-reactive protein, mg/l	−0.23	<0.001
DAS28	−0.09	0.07
Treatment group*	0.16	<0.001
R2, adjusted	0.19

*Treatment groups coded as a dummy variable: 0, methotrexate; 1, adalimumab; 2, adalimumab plus methotrexate. MCI baseline, Sharp score baseline and HAQ did not influence the model. DAS28, 28-joint disease activity score; DXR, digital x ray radiogrammetry; HAQ, health assessment questionnaire; MCI, metacarpal cortical index; RA, rheumatoid arthritis.